Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550704

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550704

Bortezomib Market, By Product Type, By Application, By End User, By Geography

PUBLISHED:
PAGES: 140 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

Global bortezomib market is estimated to be valued at USD 24.54 Mn in 2024 and is expected to reach USD 33.15 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 24.54 Mn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 4.40% 2031 Value Projection: US$ 33.15 Mn
Figure. Bortezomib Market Share (%), By Region 2024
Bortezomib Market - IMG1

Bortezomib, commonly known as Velcade, is a proteasome inhibitor that acts as a targeted cancer therapy. It has proven to be an effective treatment option for multiple myeloma and other cancers. Increasing prevalence of cancer worldwide along with growing geriatric population susceptible to myeloma can boost demand for Bortezomib. Drug being designated with orphan drug status has encouraged manufacturers to invest in this market. However, patent expiry of the drug can hamper the market growth. Promising therapeutic efficacy and expanding applications of Bortezomib can offer lucrative opportunities for the global bortezomib market growth in the near future.

Market Dynamics:

Global bortezomib market growth is driven by rising cancer burden globally. The market growth can be attributed to increasing incidence rates of multiple myeloma, approval for additional indications, and expanding geriatric population base who are more prone to developing myeloma. As per the National Cancer Institute, more than 150,000 cases of multiple myeloma were reported in the US in 2020. High treatment and R&D costs associated with Bortezomib can hamper the market growth. Patent expiry of innovative drug between 2015 to 2020 has encouraged production of generic versions, and this can negatively impact the sales of branded Velcade. However, ongoing trials evaluating the potential of Bortezomib in other disease indications can present new opportunities.

Key features of the study:

This report provides in-depth analysis of the global bortezomib market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global bortezomib market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Johnson & Johnson, Takeda Pharmaceutical Company Ltd, Fresenius SE & Co. KGaA, Dr. Reddy's Laboratories Ltd, and Scion Pharma LLC

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global bortezomib market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bortezomib market

Detailed Segmentation-

  • By Product Type Insights (Revenue, USD Mn, 2019 - 2031)
    • Injection
    • Powder for Injection
  • By Application Insights (Revenue, USD Mn, 2019 - 2031)
    • Multiple Myeloma
    • Mantle Cell Lymphoma
    • Other Hematological Malignancies
  • By End User Insights (Revenue, USD Mn, 2019 - 2031)
    • Hospitals
    • Oncology Clinics
    • Ambulatory Surgical Centers
    • Others (Research Institutes, Cancer Centers)
  • By Regional Insights (Revenue, USD Mn, 2019 - 2031)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Hikma Pharmaceuticals
    • Pfizer
    • Meitheal Pharmaceuticals
    • Novartis International AG
    • Bristol Myers Squibb
    • NATCO Pharma
    • Teva Pharmaceuticals
    • Reddy's Laboratories
    • Gland Pharma
    • Shilpa Medicare
    • Qilu Pharmaceutical
    • Scion Pharmaceuticals
    • Farmhispania Group
    • Coresyn
    • Chem-Stone (Guangzhou)
    • Hubei Honch Pharmaceutical
    • Vinkem Labs
    • Icrom
    • TAPI Teva
    • Chengdu Aslee Biopharmaceuticals
Product Code: CMI7281

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Bortezomib Market, By Product Type
    • Global Bortezomib Market, By Application
    • Global Bortezomib Market, By End User
    • Global Bortezomib Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Bortezomib Market, By Product Type, 2019-2031, (USD Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Injection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Powder for Injection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

5. Global Bortezomib Market, By Application, 2019-2031, (USD Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Multiple Myeloma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Mantle Cell Lymphoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Other Hematological Malignancies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Bortezomib Market, By End User, 2019-2031, (USD Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Oncology Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Others (Research Institutes, Cancer Centers)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Bortezomib Market, By Region, 2019 - 2031, (USD Mn)

  • Introduction
    • Market Share (%) Analysis, 2024,2027 & 2031, (USD Mn)
    • Market Y-o-Y Growth Analysis (%), 220 - 2031, (USD Mn)
    • Regional Trends
      • North America
    • Introduction
    • Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
      • GCC Countries
      • Israel
      • Rest of Middle East
      • Africa
    • Introduction
    • Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, By Country/Sub-region, 2019 - 2031, (USD Mn)
      • South Africa
      • North Africa
      • Central Africa

8. Competitive Landscape

  • Hikma Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Meitheal Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis International AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol Myers Squibb
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • NATCO Pharma
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Reddy's Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Gland Pharma
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Shilpa Medicare
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Qilu Pharmaceutical
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Scion Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Farmhispania Group
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Coresyn
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Chem-Stone (Guangzhou)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hubei Honch Pharmaceutical
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Vinkem Labs
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Icrom
  • TAPI Teva
  • Chengdu Aslee Biopharmaceuticals

9. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

10. References and Research Methodology

  • References
  • Research Methodology
  • About us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!